HapInScience Inc.

Basic Information

HapInScience Inc.

Establishment : November 22, 2018

Representative Director :
CEO Hak Bae Choi
Chief Scientific Officer Dae Kyong Kim PhD. Professor of CAU

HapInScience was established to develop new drugs to treat the diseases with medical unmet needs, which are related to tissue degeneration.

Prof. Kim found a protein, HAPLN1, which plays a key role in recovery of the tissue degenerated with aging. We are developing new drugs to treat age related disease such as Osteoarthritis, Skin aging, Alopecia etc. with the use of HAPLN 1.

The various tissue regeneration effects of HAPLN 1 will provide new solutions for the fundamental treatment of the disease with high unmet medical needs.

Business Model



- Development of anti-aging therapy
- Partnering with global pharmaceutical companies for development and marketing.
- Partnering after preparation of the preclinical data package.
- Concentrate on Pharmaceutical business at first
- Expand business scope to cosmetics and veterinary medicine in the future

2018. 11	2019. 01	2019. 03	2019. 05	2019. 07
Incorporate HapInScience	Basic Organization	Establishment of R&D Division	Certification of Corporate Research Institute	Series A Fund Raising

Organizational Chart

CEO(Chief Executive Officer)
Hak Bae Choi

CSO(Chief Science Officer)
Dae Kyong Kim

CFO
Gang Se Lee

Advisory Committee

Business Management Office

Vice President, Jong Hong Hyun

- Accounting department of Kyungpook National University
- 20 years of finance experience at pharmaceutical industry

Assistant Manager, Eun Kyung Park

Business Development Office

Director, Hyun Joo Kim

- Completed Education Center for Advanced Pharmacy at Seoul National University,
- 20 years experience in sales, marketing, and public relations in pharmaceutical industries

BD Manager, Dr. Lee Farrand

Research & Development Division
Senior Vice President, Yo Kyung Chung

Development Office

Director, Seung Yong Kim

- 15 years experienced in R&D at pharmaceuticals

IP Management Manager, Kwang-Soo Han	• IP Information Searcher • Masters Graduate School of Seoul National University
RA Manager, I Su Hong	• 10 years experienced in RA, Clinical study at pharmaceuticals
Staff, Hyun Seung Kong	• Dept. of Systems Biology, Yonsei University

Research Institute

Vice President, Woo Sik Kim

- Doctorate at Seoul National University

Principal Scientist Ji Min Jang	• Doctorate at Chungang University (HAPLN1 patent inventor)	Senior Researcher Hee Young Kim	• Busan University Graduate School of Bioscience
Principal Scientist In Chul Shin	• Doctorate at Chungang University (HAPLN1 Research)	Researcher Ju Ho Park	• Ajou University Master's at School of Medicine
Principal Researcher Eun Sook Lee	• Yonsei University Graduate School of Clinical Pathology	Researcher David Kim	• Cheonbuk National University Graduate School of BIN Convergence Engineering

HAPLN1 : **H**yaluronan **A**nd **P**roteoglycan **L**ink Protei**n** **1**

ECM (Extracellular Matrix) - Linking protein within complex structure

- **ECM (Extracellular Matrix) has a solid structure comprised of Hyaluronic Acid (HA), Collagen, Elastin.**
- **Signal transduction through various cell membrane receptors happened between cell and ECM**
- **The quantity of HAPLN1 in plasma is reduced according to aging of animal**



Dermal fibroblasts and ECM



Fibroblast on collagen fibers



Major Components of Extracellular Matrix(ECM) and Intracellular Cytoskeleton





R&D Pipeline

HAPLN1 Application



Developing HAPLN1 Therapies

Cartilage	Osteoarthritis (OA)	*DMOAD
Skin	Skin aging	Wrinkle removal, Regenerate elasticity
Hair Follicle	Hair loss (Alopecia)	Cure hair loss
Connective tissue	*CTD	Deficiency disease therapies

* DMOAD (Disease-Modifying OsteoArthritis Drug)
* CTD (Connective Tissue Disease)

Key Development Milestone & Fund

IPO is projected in 2024